3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Gastro-enteropancreatic neuroendocrine tumor
1
Acromegaly
1
Interventions
lutetium Lu 177 dotatate
2
gallium Ga 68 dotatate
2
Magnetic Resonance Spectroscopy
2
Ga(III)-DOTATOC
2
lanreotide
1
copper dotatate CU-64
1
amino-acid, glucose, and electrolyte solution
1
X-Rays
1
Radiosurgery
1
Octreotide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
E-7386
1
Disulfides
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gastro-enteropancreatic neuroendocrine tumor
×
lanreotide
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled